. 2017 Jun 16;8(32):53405–53418. doi: 10.18632/oncotarget.18509

Table 5. The association of the administration of EGFR -TKI as 1^stt-line setting and subsequent BM occurrence among 105 stage IIIB-IV patients without BM at the diagnosis of mutated-EGFR NSCLC.

Characteristics	Univariate		Multivariable
Characteristics	HR (95% CI)	P	HR (95% CI)	P
Gender (male / female)	0.65 (0.34–1.26)	0.201	0.85 (0.37–1.96)	0.704
Age (<60 /≧60)	2.44 (1.32–4.55)	0.005	2.38 (1.28–4.55)	0.007
Smoking (ever / never)	0.64 (0.29–1.40)	0.263	0.78 (0.29–2.15)	0.634
Histology (adenocarcinoma/non-adenocarcinoma)	0.56 (0.10–3.15)	0.509	0.66 (0.10–4.24)	0.660
1^st-line TKI (yes / no)	2.11 (1.15–3.89)	0.016	2.10 (1.15–3.82)	0.015

EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; BM: brain metastasis; NSCLC: non-small cell lung cancer; HR: hazard ratio; CI: confidence interval. # The association between the administration of EGFR-TKI and subsequent BM was tested using a time-to-event analysis considering death as a competing risk (Fine and Gray's sub-distribution hazard model).

Table 5. The association of the administration of EGFR -TKI as 1stt-line setting and subsequent BM occurrence among 105 stage IIIB-IV patients without BM at the diagnosis of mutated-EGFR NSCLC.

Table 5. The association of the administration of EGFR -TKI as 1^stt-line setting and subsequent BM occurrence among 105 stage IIIB-IV patients without BM at the diagnosis of mutated-EGFR NSCLC.